After announcing the state would initiate coverage of GLP-1s to combat obesity in September 2022 as part of their state employee health plan, the state reversed course and in January 2025 announced it was opting to end that coverage beginning July 1, 2025
Who may benefit most from GLP-1 therapies
Include a letter of medical necessity from your provider, documentation of all qualifying comorbidities, evidence of failed prior weight loss attempts, and any supporting metabolic data
Similarly, liraglutide for diabetes (Victoza) starts at 0.6 mg daily, escalating to 1.2 mg and potentially 1.8 mg if needed, while liraglutide for weight management (Saxenda) follows a schedule from 0.6 mg to 3.0 mg daily (via 1.2 mg, 1.8 mg, and 2.4 mg steps)
This approach focuses on stimulating the bodys natural collagen response rather than relying on surgical methods
Decide where you will inject the GLP-1